1/20
08:00 am
ltrn
Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas
Low
Report
Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas
1/12
09:12 am
ltrn
Lantern Pharma Announces Establishing an A.I. Center of Excellence in India to Industrialize the RADR® Platform and Accelerate Global Development Opportunities with BioPharma Companies [Yahoo! Finance]
Medium
Report
Lantern Pharma Announces Establishing an A.I. Center of Excellence in India to Industrialize the RADR® Platform and Accelerate Global Development Opportunities with BioPharma Companies [Yahoo! Finance]
1/12
09:00 am
ltrn
Lantern Pharma Announces Establishing an A.I. Center of Excellence in India to Industrialize the RADR® Platform and Accelerate Global Development Opportunities with BioPharma Companies
Medium
Report
Lantern Pharma Announces Establishing an A.I. Center of Excellence in India to Industrialize the RADR® Platform and Accelerate Global Development Opportunities with BioPharma Companies
12/27
05:06 pm
ltrn
New to The Street Show #710 Airs Tonight at 6:30 PM EST on Bloomberg Television [Yahoo! Finance]
Low
Report
New to The Street Show #710 Airs Tonight at 6:30 PM EST on Bloomberg Television [Yahoo! Finance]
12/9
04:25 pm
ltrn
Lantern Pharma (NASDAQ:LTRN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Lantern Pharma (NASDAQ:LTRN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
12/3
08:35 am
ltrn
Lantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision Oncology Program into Multiple Biomarker-Guided Phase 1b/2 Trials
Medium
Report
Lantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision Oncology Program into Multiple Biomarker-Guided Phase 1b/2 Trials
11/25
01:53 pm
ltrn
Lantern Pharma (NASDAQ:LTRN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Lantern Pharma (NASDAQ:LTRN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/15
07:42 am
ltrn
Lantern Pharma (NASDAQ:LTRN) Will Have To Spend Its Cash Wisely [Yahoo! Finance]
Medium
Report
Lantern Pharma (NASDAQ:LTRN) Will Have To Spend Its Cash Wisely [Yahoo! Finance]
11/13
01:17 pm
ltrn
Lantern Pharma Inc. (LTRN) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
Lantern Pharma Inc. (LTRN) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/13
08:48 am
ltrn
Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates [Yahoo! Finance]
Medium
Report
Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates [Yahoo! Finance]
11/13
08:30 am
ltrn
Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates
Low
Report
Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates